Genmab Announces Financial Results for the Nine Months of 2025

November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025 Highlights Announcement of Genmab’s proposed acquisition of Merus N.V. (Merus)Genmab revenue increased 21% compared to the first nine months of 2024, to $2,662 millionFDA granted BTD to Rina-S® in advanced endometrial cancerEpcoritamab Phase 3 EPCORE® FL-1 trial met dual primary endpoints of ORR and PFS, demonstrating statistically significant and clinically meaningful differences in both endpointsFDA granted p ...